Dicot

The goal of the Sexual Medicine Society North America (SMSNA) is to promote, encourage and support the highest standards of practice, research, education and ethics in the study of human sexual functions and dysfunctions. At the annual congress in San Diego at the end of November, the preclinical research results behind Dicot's potency drug candidate LIB-01 will be presented.

Professor François Giuliano will give the presentation. He is a clinically active urologist in France, a widely published author in scientific journals and has won several international awards in the field of sexual medicine. Professor Giuliano is also one of the founders of the contract laboratory Pelvipharm and was responsible for all preclinical effect studies carried out with LIB-01. Dicot will also be represented by Charlotta Gauffin, the company's Chief Scientific Officer.

"I am delighted to introduce the exciting findings regarding LIB-01, including its extended duration of effect and its differentiated mode of action, which sets it apart from currently available drugs. In my daily interactions with patients experiencing erectile dysfunction, I am acutely aware of the pressing need for new improved treatments. LIB-01 has the potential to make a meaningful impact”, comments Professor Giuliano.

"Coming out with our research results internationally is something we focus a lot on now as we have stepped into the clinic phase with LIB-01. Now American top researchers and physicians can learn the positive results from our preclinical program and we were proud and happy that Professor François Giuliano, who is a well-known expert in the field, offered to give the presentation," says Dicot CEO Elin Trampe.  

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,400 shareholders. For more information, please visit www.dicot.se.